Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Net Income (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Net Income for 4 consecutive years, with -$21.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income rose 67.53% to -$21.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$107.3 million, a 47.57% increase, with the full-year FY2025 number at -$107.3 million, down 12.44% from a year prior.
  • Net Income was -$21.3 million for Q4 2025 at Day One Biopharmaceuticals, down from -$19.7 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $35.8 million in Q3 2024 to a low of -$112.4 million in Q2 2024.
  • A 4-year average of -$40.2 million and a median of -$38.9 million in 2022 define the central range for Net Income.
  • Peak YoY movement for Net Income: skyrocketed 177.66% in 2024, then crashed 154.94% in 2025.
  • Day One Biopharmaceuticals' Net Income stood at -$40.1 million in 2022, then tumbled by 35.95% to -$54.5 million in 2023, then decreased by 20.58% to -$65.7 million in 2024, then skyrocketed by 67.53% to -$21.3 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Net Income are -$21.3 million (Q4 2025), -$19.7 million (Q3 2025), and -$30.3 million (Q2 2025).